March 19, 2014
For immediate release
Contact: Gerry Ewing / 503-681-1654
The Tuality/OHSU Cancer Center is pleased to announce that oncologist Timur Mitin, M.D., Ph.D., has joined the joint venture as medical director.
Mitin, who specializes in the field of radiation oncology and joined Oregon Health & Science University (OHSU) this year, has practiced and trained at several of the nation’s leading academic health-care institutions including Harvard Medical School at Massachusetts General Hospital.
Mitin succeeds Charlotte Dai Kubicky, M.D., Ph.D., who joined the cancer center as medical director in 2007. Kubicky will continue in her role as an assistant professor for the OHSU Knight Cancer Institute, as well as seeing patients at the OHSU Knight Cancer Institute clinic in Beaverton.
Mitin is a native of Moscow, Russia, who came to the United States at age 16 to pursue his education. He received his B.A., cum laude, in chemistry and biology at Cornell University in Ithaca, N.Y. He pursued his medical training in a combined M.D./Ph.D. program at Tufts University School of Medicine in Boston.
“We are delighted to have Dr. Mitin join us at the Tuality/OHSU Cancer Center,” said Tina Dickerson, cancer center director. “His credentials are amazing, and we as a cancer care team look forward to what he will bring to our program. At the same time, I would like to thank Dr. Kubicky for her years of service. She is an outstanding physician, and both our patients and our group here will miss her.”
During his doctoral training, Mitin studied cancer immunology and defended his thesis work on hormonal regulation of drug metabolism. Upon graduating from Tufts, he completed an internship year in internal medicine at Providence St. Vincent Hospital in Portland, and returned to Boston for his training in radiation oncology at the Harvard University Radiation Oncology Program.
After completing his residency program, he was invited to join the faculty of Harvard Medical School at the Massachusetts General Hospital, where he specialized in treatment of patients with genitourinary malignancies.
Mitin is a first author of several review articles as well as Radiation Therapy Oncology Group publications in the field of bladder preservation in patients with muscle-invasive bladder cancer. He has lectured extensively on a variety of radiation oncology related topics.
“I’m looking forward to joining the Tuality/OHSU Cancer Center staff and bringing cutting edge cancer treatment practices to patients in Hillsboro,” Mitin said. “One of my first tasks will be to meet the many providers in the community and discuss how we can team up to provide the best care possible for our patients.”
The Tuality/OHSU Cancer Center is a joint venture between Tuality Healthcare and the Knight Cancer Institute at Oregon Health & Science University to deliver advanced cancer care to patients in the Hillsboro community.